Last reviewed 2026-04-22 · How we verify

Risankizumab (RISA)

Risankizumab is a monoclonal antibody that selectively inhibits the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.

Risankizumab is a monoclonal antibody that selectively inhibits the IL-23 cytokine pathway by binding to the p19 subunit of IL-23. Used for Moderate to severe plaque psoriasis, Crohn's disease, Ulcerative colitis.

At a glance

Mechanism of action

IL-23 is a key driver of inflammatory responses in immune-mediated diseases. By blocking the p19 subunit of IL-23, risankizumab prevents IL-23 signaling and reduces the differentiation and activation of pro-inflammatory T cells, particularly Th17 cells. This leads to decreased inflammation in conditions like psoriasis and inflammatory bowel disease.

Approved indications

• Moderate to severe plaque psoriasis
• Crohn's disease
• Ulcerative colitis

Common side effects

• Upper respiratory tract infection
• Headache
• Injection site reactions
• Nasopharyngitis

Key clinical trials

• Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
• VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Risankizumab (RISA) CI brief — competitive landscape report
• Risankizumab (RISA) updates RSS · CI watch RSS
• Caja Costarricense de Seguro Social portfolio CI